News

Show
news from

Freeline Announces Closing of Sale of Its CMC-Focused German Subsidiary

Freeline Publishes Preclinical Proof-of-Concept Data for FLT190, its AAV Gene Therapy Candidate for Fabry Disease, in the Nature Journal Gene Therapy

SwanBio Therapeutics Initiates First-in-Human Study of AAV Gene Therapy for Adrenomyeloneuropathy

Freeline Receives Approval to Transfer to Nasdaq Capital Market

Purespring Chief Executive Officer Richard Francis appointed Chief Executive Officer of Teva Pharmaceutical Industries Ltd

Freeline Reports Third Quarter 2022 Financial Results and Corporate Update

Load more

Search